Moderna said it's working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after FDA leaders narrowed the label.
May 1, 2026 02:08 PM EDTUpdated 02:44 PM
Moderna in talks with FDA over post-marketing Covid shot data, with eyes on wider access
Moderna said it’s working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the…
The pharmaceutical giant expressed optimism that its new flu shot would be available this year, after approval concerns.
Amid RFK Jr.'s anti-vaccine agenda, Moderna withdrew its FDA application last year.
Analysts pointed to an upcoming health care conference and cancer data study release as potential catalysts for Moderna's ongoing…
Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialog with the FDA—but…
Moderna's mRNA-1010 flu vaccine for older adults could be made available by the end of 2026, the pharmaceutical company announced…
